Matthew Davids, MD, from Dana-Farber Cancer Institute, Boston, MA outlines the importance of being aware of a patient’s tumor lysis risk status in chronic lymphocytic leukemia (CLL). This status can be determined by the the size of their lymph nodes and the height of their lymphocytosis. Dr Davids continues on to emphasize the importance starting venetoclax treatment at a low dose and ramping the dosage up week by week. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
The importance of considering a CLL patient’s tumor lysis risk status
